Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06604520 · ClinicalTrials.gov registry record · Phase 2
Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
A Phase 2 study of Frontotemporal Dementia and Frontotemporal Degeneration, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06604520: Recruiting Phase 2 study of Frontotemporal Dementia and Frontotemporal Degeneration, sponsored by Johns Hopkins University.
NCT06604520 is a Phase 2 study of Frontotemporal Dementia and Frontotemporal Degeneration that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 50 participants, below the 1,195-participant average among 22 other Frontotemporal Dementia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06604520, a Phase 2 study of Frontotemporal Dementia and Frontotemporal Degeneration, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are: 1. Do individuals with mood symptoms and bvFTD have brain changes and cognitive profiles that differ compared to individuals without bvFTD? 2. Do mood symptoms and cognition improve following treatment with vortioxetine? Researchers will also determine whether there are changes in the brain associated with vortioxetine treatment. Participants will: * Undergo a screening visit that involves clinical assessments and laboratory tests * Undergo an initial brain magnetic resonance imaging (MRI) and fluorodeoxyglucose (18F) Positron Emission Tomography (FDG PET) scan before starting treatment with vortioxetine * Undergo memory and problem-solving tests before starting treatment with vortioxetine * Undergo approximately 12 weeks of treatment with vortioxetine, during which time there will be regular contact and assessments with the study psychiatrist * Undergo a repeat PET scan and repeat memory and problem-solving tests after 12 weeks of treatment with vortioxetine
Primary Outcome
Cerebral glucose uptake measured through 18F FDG positron emission tomography
Conditions Studied
Interventions
- DRUG Vortioxetine
Study Locations (1)
Maryland
- The Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2029-09-01 |
| Phase | Phase 2 |
What NCT06604520 shows while recruiting
NCT06604520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,195-participant average among 22 other Frontotemporal Dementia trials with a reported enrollment target (96% lower).
The record links to 5 conditions, with Frontotemporal Dementia appearing as the primary indexed condition, and to 1 intervention - of which Vortioxetine is the first listed.
NCT06604520 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06604520 about?
NCT06604520 is a clinical study titled "Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia". The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are: 1. Do individuals with mood symptoms and bvFTD have brain changes and c...
What is the current status of trial NCT06604520?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-03-20. Estimated completion is 2029-09-01.
What conditions does trial NCT06604520 study?
This clinical trial studies the following conditions: Frontotemporal Dementia, Frontotemporal Degeneration, Fronto-temporal Lobar Dementia, Frontotemporal Dementia (FTD), Frontotemporal Dementia, Behavioral Variant.
What interventions are being tested in trial NCT06604520?
The interventions under investigation include: Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT06604520?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06604520 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Frontotemporal Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06604520's enrollment target sits among peer trials
50 17th of 22 higher than 5 of 22 other Frontotemporal Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Frontotemporal Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD
ACTIVE NOT RECRUITING · Phase 2
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
-
Longitudinal Cognitive Assessment by BoCA
RECRUITING
-
Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
RECRUITING
-
NYSCF Scientific Discovery Biobank
RECRUITING
-
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI